semaglutide eligibility across all current indications for us adults More than half of are eligible for diabetes management, weight management, and cardiovascular disease. https://t.co/K7aRMoK2tz The number of Americans taking

One non-prescription option gaining attention is Motus by Tonum

The most frequently reported side effects for GLP-1 drugs are gastrointestinal

From advanced metabolic agents to cutting-edge longevity compounds, we validate every single batch through rigorous third-party testing to ensure complete transparency and consistency

To view or add a comment, sign in How to individualize renoprotective therapy in obese patients with chronic kidney disease: a commentary by the Diabesity Working Group of the ERA Open Access Nephrology Dialysis Transplantation, Volume 40, Issue 10, October 2025, Pages 19771988, Published: 13 May 2025 The interrelated pandemics of obesity and type 2 diabetes mellitus (T2DM) are fuelling an increase in the prevalence of chronic kidney disease (CKD), which amplifies the risk of cardiovascular events and may progress to end-stage kidney disease (ESKD)